Purpose: The objective of this multicenter study was to compare the efficacy and toxicity profiles of a combination of 5-fluorouracil (5-FU) given by bolus injection together with intravenous leucovorin (LV) versus high-dose 5-FU in continuous infusion (CI) in the treatment of advanced colorectal cancer.
Introduction
Colorectal cancer has traditionally been considered resistant to chemotherapy. Since its introduction in clinical oncology 40 years ago, 5-FU remains the most useful single-agent treatment for this disease, with a low response rate and no significant effect on survival [1, 2] . Despite an important effort to determine whether altering the dose level or the method of administration can increase the efficacy of 5-FU, it is still not clear whether the optimum procedure for administering the drug is alone or modulated. Several studies have suggested that the continuous infusion of 5-FU increases the response rate, which could be related to the higher dose intensity administered [3] [4] [5] .
Phase I-II and phase II trials of a weekly high-dose 48-hour continuous infusion of 5-FU established a maximum tolerable dose of 3.5 g/m 2 [6] with mucositis and diarrhea as limiting toxic effects and a response rate of 43% and 38.5%, respectively [7] . A further phase II trial attempted to modulate the high-dose (3 g/m 2 ) continuous 5-FU weekly infusion with oral LV but this schedule yielded high toxicity and the dose had to be reduced [8] . Another study was then carried out with the lower dose of 5-FU 2 g/m 2 plus oral LV achieved in the previous trial, and an objective response rate of 37.5% was obtained in a total of 110 patients, with mucositis and diarrhea remaining the main limiting toxic effects [9] . The dose intensity which in the phase II trial with 5-FU without modulation was 3 g/m 2 /week fell to 1.6 g/m 2 / week. 5-FU administered in continuous infusion(CI) plus oral LV is an active regimen but does not appear to be superior to 5-FU alone administered in the same schedule at 3.5 g/m 2 . All these studies suggested that when high-dose CI 5-FU was used at maximum dose intensity, the modulating effect of LV was needed to increase tumor response.
To test this hypothesis, the TTD group planned a phase III study to determine whether our CI schedule without modulation was superior in response rate to the schedule which at that moment could be considered as standard: the monthly low-dose LV with 5-FU bolus schedule. This schedule was shown by investigators at the Mayo Clinic to increase patient survival (in those with measurable disease), interval to progression and tumor response, and to enhance quality of life more than 5-FU bolus alone [10] . On the other hand, it has been used in the other randomized trials as control arm [11, 12] . This paper reports the final results.
Patients and methods

Eligibility criteria
Eligibility criteria were histologically confirmed colorectal cancer, measurable disease and no previous chemotherapy. Patients exposed to pelvic radiation were eligible if there was at least one measurable lesion outside the radiotherapy field. Other inclusion criteria were age less than 75, life expectancy of at least two months, ECOG performance status less than 3, more than 4000 leukocytes/ml and more than 150,000 platelets/ml at entry, bilirubin < 1.5 mg/dl and creatinine < 1.2 mg/dl. All patients provided informed consent according to institutional ethics committee guidelines. Patients were excluded from the study if they had received any previous chemotherapy, except for adjuvant chemotherapy if given at least one year before the development of mctastatic disease. The study did not include patients whose only reference was non-measurable disease, central nervous system metastasis, a second neoplasm except for non-melanoma skin cancer or a properly treated in situ cervical cancer. Measurable disease was defined as the presence of at least one lesion larger than 2 cm, clearly bidimensionally measured by clinical examination, computer tomographic scan (CT), X-ray or ultrasound.
Randomization
From June 1994 until November 1996, 306 consecutive patients were randomized to receive either the NCCTG-Mayo Clinic schedule: Arm A or the TTD high-dose 5-FU Cl schedule: Arm B. Randomization was centralized by phone call in the data center. After checking the eligibility criteria, the patients were allocated to one of the trial arms.
Chemotherapy
Arm A
Patients received monthly 5-FU bolus plus low-dose LV for five consecutive days. LV was given by bolus at 20 mg/m 2 /day and was followed immediately by 5-FU given by rapid intravenous infusion at 425 mg/nr/day, repeated for five consecutive days. Cycles 1 and 2 were administered every four weeks. Thereafter cycles were given every five weeks. In instances of grade 3 leukopenia, mucositis or diarrhea, the 5-FU dose was reduced by 25% and delayed for at least one week until complete disappearance of toxicity. If grade 2 mucositis or diarrhea appeared, the dose of 5-FU was not modified but treatment was delayed for at least one week until complete disappearance of all toxicity.
ArmB
Patients received 3.5 g/m 2 of 5-FU administered in 500 ml of normal saline in a 48-hour infusion every week, as outpatients, by portable infusion pumps and subcutaneous port.
Patients were withdrawn from the study when unacceptable toxicity or progressive disease appeared. If leukopenia, mucositis or diarrhea of grade 3-4 were observed, the dose of 5-FU was reduced by 50% for the next cycles. If grade 2 mucositis or diarrhea appeared, the 5-FU was reduced by 25%. In all cases, 5-FU was restarted when all manifestations of toxicity had completely disappeared.
In the presence of disease progression, the study regimen was stopped. Cross-over treatment and second-line therapy were allowed.
Study parameters
WHO criteria were used for the definition of response, response duration and toxicity [13] . Complete response (CR) was defined as the disappearance of all known disease, determined by two observations not less than four weeks apart. Partial response (PR) was defined as a 50% or greater decrease in the sum of the products of the two largest perpendicular diameters of all measurable lesions measured by two observations not less than four weeks apart. In addition, no manifestation of new lesions or progression of any preexisting lesions could be observed. Stable disease was defined as a decrease in total tumor size ofless than 50% or a less than 25% increase in the size of one or more measurable lesions. Response was assessed after eight weeks of therapy. During treatment, every four weeks the following examinations and tests were performed: Physical examination, complete blood cell count, measurement of aspartate and alanine aminotransferase, creatinine, alkaline phosphatase and lactate dehydrogenase. All tests needed for response evaluation were repeated every eight weeks.
Statistical consideration
With an expected response rate to the 'standard' treatment (Arm A) of 23%, the sample size was calculated in order to detect an increase of 15% in response rate with arm B, with an alpha error = 0.05 and a power (1-beta) = 0.80; 132 patients per arm were required with an accrual of three years. Objective response rates were compared by means of Fisher's exact [14] and Pearson's chi-square tests [15] . The 95% exact confidence interval was also calculated [16] . Survival and time to progression curves were constructed using Kaplan-Meier product-limit estimators [17] .
Results
Patient characteristics
During the 30 months of accrual, 151 patients were randomized to arm A, and 155 to arm B. Their characteristics are shown in Table 1 : the two groups were wellmatched in terms of their demographic data, performance status and sites of disease. The median number of single-organ sites with metastasis in both groups was one, the majority of cases were Dukes' stage D at the moment of diagnosis, and the majority of the patients also had a good performance status (ECOG 0-1).
The median number of courses administered was five, range 1-22 (arm A) and 18, range: 1-57 (arm B), the 5-FU dose intensities obtained were 0.53 and 3.1 g/m 2 /week, respectively.
Objective tumor responses
The modulated schedule produced a 2% complete response rate and a 17.2% partial response rate, for an overall objective response rate of 19.2% (95% confidence interval (95% Cl): 12%-29%). The continuous-infusion schedule produced a 4% complete response rate and a 26 .3% partial response rate, for an overall objective response rate of 30.3% (95% CI: 24%-39%).The difference was statistically significant (P < 0.05). The median duration of responses was similar in both arms, 19 versus 20 weeks (Table 2) . Response by site is listed in Table 3 , which shows response in all sites.
Survival and time to progression
The median time to progression was similar in both arms (23.5 versus 25 weeks, Figure 1) . The median overall survival was 42.5 weeks for the 5-FU + LV arm and 48 weeks for the CI arm (P = ns, Figure 2 ).
Toxicity
The side effects observed are listed in Table 4 : considering the worst level of toxicity occurring in each case we have found no significant differences in relation to the grade 3-4 toxicities in either of the arms. The hematological toxicity found was low in both schedules. If we consider all grades we observed more mucositis in the modulated arm and more hand-foot syndrome in the CI arm. With respect to cardiac toxicity the majority of the events produced were dysrhythmias which did not require treatment. In the continuous-infusion arm there were four patients with grade 3-4 toxicity. The first presented a dysrhythmia which needed treatment, two patients suffered angina pectoris without infarct and the fourth had acute infarct of the myocardium. In no case was a clear relationship between the cardiotoxicity and 
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Discussion
Since 1957 when Heidelberger synthesized 5-FU, it has been administered in many different schedules, dosages and routes for colorectal cancer treatment, and we still do not know which is the optimal schedule. The response rate for 5-FU bolus is between 10% and 20% but complete response is exceptional, of short duration and there is no improvement in survival [1, 2] . It has been demonstrated that 5-FU modulation, mainly with LV, improves the results obtained with 5-FU alone, although the impact on survival is still not clear [18] . A meta-analysis has shown that the combination 5-FU + LV yields a higher percentage of response (23%) than 5-FU alone (11%). This difference is statistically significant, but there is no improvement in survival. The authors explain this by the facts that the overall response rate is far less than 50%, the complete responses are anecdotal and cross-over treatment was allowed after progression [19] .
There are tumor cell kinetics as well as pharmacological considerations that may explain the low response rates observed in colorectal cancer when 5-FU is administered as a rapid bolus injection. As with other antimetabolites, 5-FU is more effective against tumor cells that are in active cell division. Colorectal cancer is a slow-growing tumor with most tumor cells in grade 0 or resting phase and only a small proportion in the susceptible S phase. This may be one of the reasons why 5-FU when given by rapid push injection, will kill only a small proportion of malignant cells. On the other hand, owing to its rapid catabolism, the serum half-life of 5-FU is very short, not exceeding 11 minutes and tumor cells are therefore exposed to the drug for only a short period of time. Continuous infusion of 5-FU can be considered a better regimen than bolus infusion in advanced colorectal cancer in terms of response rate and toxicity profile. Moreover, a recently published meta-analysis of several trials of CI 5-FU has shown that there is some small but significant improvement in survival [3] [4] [5] [20] [21] [22] [23] [24] .
According to Hryniuk's hypothesis [25] , dose intensity is an important aspect of the pharmacological approach to advanced colorectal cancer. In the different studies we have carried out, it is clear that if modulation of high-dose 5-FU is attempted, more toxicity will be observed without any increase of antitumor activity [26] . On the other hand, the meta-analysis of 5-FU versus 5-FU plus LV showed that no advantage was obtained in the modulation arm when controls were treated with high-dose 5-FU. Moreover, a randomized trial showed no benefit from the addition of oral LV to bolus 5-FU versus equitoxic doses of 5-FU [27] .
The present study demonstrates that the high-dose 5-FU CI is superior to the Mayo Clinic schedule in terms of response rate. The overall response rate for the CI arm is 30.3% and for the 5-FU + LV 19.2% (P < 0.05). The median duration of responses was similar in the two arms, as well as the median time to progression and overall survival. The trial was designed to detect a 15% difference in response rate between arms. Time to progression and survival were only secondary objectives and the trial was not designed to detect differences in these parameters. In fact, second-line chemotherapy was permitted and some patients were crossed over to the other arm upon progression.
According to the intent-to-treat principle, all randomized patients were included in the analysis for response and survival, independently of treatment compliance. In fact, we included patients in the analysis with early death, treatment refusal after randomization, protocol violation who were lost to follow-up during the first month, which amounted to 6% of registered patients for the CI arm and 4% for the 5-FU + LV. This purist analysis of clinical trials is the one most often recommended by experts on statistics in order to prevent bias, even if it could dilute the estimate of treatment effect [28, 29] .
In our trial we have found no differences in the incidence or severity of toxicity in the two arms. The toxicity profile of our continuous infusion schedule is similar to the one previously published in our phase II trial [7] . However, the toxicity of the Mayo Clinic schedule is lower than was previously reported by other investigators [10] [11] [12] . In our study, toxicity in both arms was assessed by the participating investigators every four weeks. Nevertheless, patients receiving CI 5-FU came to the hospital every week to receive chemotherapy and could thus be seen by doctors if they presented any toxic event. On the other hand, patients randomized to Arm A came to the hospital every four weeks to receive therapy and to report retrospectively on the toxicity suffered. So we do believe that there might have been a bias at the time of grading toxicity. The real grading of toxicity may have been down-staged by the patients when they referred to the adverse events several weeks after their presentation. The lower incidence of toxicity may also be explained by the small proportion of patients with performance status 2. Most of the patients in our trial (82%) have PS 0-1. Patients with poor performance have a higher probability of suffering from more severe toxicity. However, this proportion does not differ significantly from other studies in which toxicity is more severe.
In short, weekly high-dose CI 5-FU clearly increased the response rate over that of the Mayo Clinic schedule and also reduced the proportion of patients progressing early on therapy. This study did not consider as an aim the evaluation of quality of life and other related parameters, which will be very important in future trials. Our results in general agree with those of other randomized studies performed until now. All the studies show a benefit in relation to the therapeutic ratio for CI arms, but without clinically significant effect on overall survival. A large pan-European randomized study (PETACC-2) in the adjuvant setting plans to determine the definitive importance of the CI of 5-FU in the treatment of colorectal cancer.
